nisoldipine Side Effects
Also known as: Sular
Analysis of 1,191 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
1,191
Death-Related
123
10.3% of reports
Hospitalizations
394
33.1% of reports
Top Indication
Hypertension
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 123 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 39 |
| RENAL FAILURE | 21 |
| MYOCARDIAL INFARCTION | 19 |
| COMPLETED SUICIDE | 17 |
| INJURY | 14 |
| ASTHENIA | 13 |
| CARDIAC FAILURE CONGESTIVE | 12 |
| PAIN | 12 |
| PNEUMONIA | 12 |
| ANXIETY | 11 |
| DYSPNOEA | 10 |
| RESPIRATORY FAILURE | 9 |
| CHRONIC KIDNEY DISEASE | 8 |
| DIARRHOEA | 8 |
| NAUSEA | 8 |
| WEIGHT DECREASED | 8 |
| ANHEDONIA | 7 |
| ATRIAL FIBRILLATION | 7 |
| DIZZINESS | 7 |
| END STAGE RENAL DISEASE | 7 |
Reactions in Hospitalization Reports
Top reactions in 394 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 43 |
| MYOCARDIAL INFARCTION | 39 |
| CARDIAC FAILURE CONGESTIVE | 35 |
| RENAL FAILURE | 35 |
| ASTHENIA | 34 |
| NAUSEA | 33 |
| PAIN | 33 |
| ANXIETY | 31 |
| CEREBROVASCULAR ACCIDENT | 31 |
| PNEUMONIA | 31 |
| DIARRHOEA | 29 |
| DIZZINESS | 27 |
| FATIGUE | 26 |
| CORONARY ARTERY DISEASE | 25 |
| HEADACHE | 24 |
| HYPERTENSION | 24 |
| BACK PAIN | 23 |
| CHEST PAIN | 23 |
| ATRIAL FIBRILLATION | 22 |
| INJURY | 22 |
Nearby — Related Medications
What the FAERS Data Reveals About nisoldipine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,191 voluntary reports linked to nisoldipine and its brand equivalents (Sular), spanning 2004 through 2025. Of those, 123 (10.3%) listed death as an outcome and 394 (33.1%) involved hospitalization. The most common indication reported alongside adverse events was Hypertension.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 62% were female and 38% male; age distribution skews toward 45-64, with 264 reports in that bracket. The single most reported reaction is nausea with 88 submissions, followed by drug ineffective and dizziness.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.